(MedPage Today) — Treatment with setmelanotide (Imcivree), a melanocortin-4 receptor (MC4R) agonist, led to significant reductions in body mass index (BMI) and hunger in individuals with acquired hypothalamic obesity, the phase III TRANSCEND trial…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
